Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Procaine→

Procaine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
59-46-1
Molecular formula
C13H20N2O2
Molecular weight
236.31 g/mol
Drug class
Ester-type local anaestheticpara-aminobenzoic acid derivative
Mechanism of action
Blocks voltage-gated sodium channels in neuronal membranes, preventing initiation and conduction of nerve impulses and producing reversible local anaesthesia. It is hydrolysed by plasma esterases to para-aminobenzoic acid and diethylaminoethanol.
Indications / reported uses
  • Local anaesthesia for infiltration and selected regional anaesthetic procedures using authorised injectable formulations; current use is limited in many jurisdictions because of shorter duration and availability of alternative local anaesthetics

Sources: NLM MeSH — Procaine · PubMed — Procaine local anaesthetic mechanism · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Procaine Environmental Risk Assessment (ERA) (the Procaine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.